Compare AstraZeneca plc (AZN) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs BlackRock TCP Capital Corp — how do they compare? AstraZeneca plc trades at $158.52 (market cap $248.14B), while BlackRock TCP Capital Corp trades at $3.97 (market cap $327.64M). The key difference: AstraZeneca plc is far larger — about 757.4× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays the higher dividend (19.46%). Which is the better fit depends on your goals.
| AZN | TCPC | |
|---|---|---|
Market Cap | $248.14B | $327.64M |
Sector | Health | Financials |
52-Week High | $209.48 | $7.26 |
52-Week Low | $147.06 | $3.13 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | 19.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
TCPC trades at $3.92, down 0.51% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent Q2 2026 earnings beat expectations at $0.22 per share, and the company completed a $523 million portfolio sale to reduce leverage. However, fundamentals show negative revenue and net income trends, with a high P/S ratio of 70.7 but a discounted P/B of 0.59.
The outlook is mixed: strategic actions and dividend yield near 8.7% offer value, but declining revenue, negative ROE/ROA, and class-action lawsuits pose significant risks. Analyst consensus is cautious with 30.8% buy ratings, suggesting limited upside without fundamental improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
